Reproductive and Developmental Medicine

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 3  |  Issue : 3  |  Page : 153--158

Therapeutic effect of metformin on patients with polycystic ovary syndrome with normal insulin sensitivity: A retrospective study


Wan-Wan Liu1, Dong-Hai Li2, Xue-Zhen Luo2, Ling-Li Tang2, Ying-Li Shi3 
1 Department of Health Management, Renji Hospital, Shanghai Jiao Tong University, Shanghai 200127, China
2 Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090, China
3 Department of Gynecology, Obstetrics and Gynecology Hospital; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai 200090, China

Correspondence Address:
Ying-Li Shi
Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090
China

Objective: This study aimed at elucidating the therapeutic effectiveness of metformin in polycystic ovary syndrome (PCOS) patients with normal clinical indices of insulin sensitivity. Methods: This study was a retrospective cohort study. Based on their homeostasis model of assessment of insulin resistance (HOMA-IR) results, PCOS patients (n = 113) were allocated to either the IR Group (IR, HOMA-IR >2.69) or the non-IR Group (NIR, HOMA-IR ≤2.69). Metformin was administered to all patients, and their medical history, menstrual status, and endocrine and metabolic characteristics were obtained before and after treatment. The one-way analysis of variance was used to determine the differences between the IR and NIR groups. The paired t-test was used to determine the differences between pre- and posttreatment results. Results: Analyses of baseline characteristics showed that the incidence of IR and glycolipid metabolism is higher within elder PCOS patients. Metformin improved menstrual cycle and ovulation rate in NIR patients, similar to those in IR patients. In the NIR group, metformin decreased luteinizing hormone (LH) levels, free androgen index (FAI) levels, body mass index, and waist circumference, but had no obvious effect on glucose, insulin, and lipid profiles. Whereas in the IR group, metformin not only decreased LH and FAI levels, but also improved glycolipid metabolism. Conclusions: The effect of metformin on PCOS patients with normal insulin sensitivity index suggests that the mechanism of menstrual improvement may not be related to IR. In addition, metformin can improve glycolipid metabolism. Therefore, metformin is suitable for long-term treatment of PCOS and should be more widely used.


How to cite this article:
Liu WW, Li DH, Luo XZ, Tang LL, Shi YL. Therapeutic effect of metformin on patients with polycystic ovary syndrome with normal insulin sensitivity: A retrospective study.Reprod Dev Med 2019;3:153-158


How to cite this URL:
Liu WW, Li DH, Luo XZ, Tang LL, Shi YL. Therapeutic effect of metformin on patients with polycystic ovary syndrome with normal insulin sensitivity: A retrospective study. Reprod Dev Med [serial online] 2019 [cited 2019 Nov 19 ];3:153-158
Available from: http://www.repdevmed.org/article.asp?issn=2096-2924;year=2019;volume=3;issue=3;spage=153;epage=158;aulast=Liu;type=0